Jiangsu Enhua Pharmaceutical Co., Ltd

Enhua nhwa

Jiangsu Enhua Pharmaceutical Co., Ltd. is a pharmaceutical enterprise integrating science, industry and trade, a high-tech enterprise, a national top 100 pharmaceutical enterprises, a listed enterprise, a vice president unit of China narcotic drugs Association, a vice president unit of Jiangsu Pharmaceutical Industry Association, and a designated production unit of psychotropic drugs of the Ministry of health.

Jiangsu Enhua Pharmaceutical Co., Ltd. is a pharmaceutical enterprise mainly engaged in the development, production and sales of central nervous system drugs. It is the only enterprise in the domestic pharmaceutical industry that focuses on the market segmentation of central nervous system drugs. The main categories include anesthetics, psychiatry and neurology. Through years of unremitting efforts in product research and development, production and service, the company has been established Establish a complete central nervous system drug product series and marketing network, and strive to build an important manufacturer and distributor of central nervous system drugs in China. In addition, the company has a series of cardiovascular and cerebrovascular products in different research and development stages. Among them, the national first-class antihypertensive drug iptakalim, which is developed in cooperation with the National Academy of Military Medical Sciences, is the first in China and abroad. It has a new chemical structure and mechanism of action, and is in a leading position in the world. It is gradually involved in the cardiovascular and cerebrovascular drug market with broad market prospects. The company has three large-scale GMP production bases for API and preparation drugs, covering a total area of more than 600 mu. The company has national certified API workshop, solid preparation workshop, water injection workshop, freeze-dried powder injection workshop, and more than 10 automatic production lines for tablets, capsules, water injection, powder injection and granules. At present, it has a production scale of 28 kinds of raw materials, 550 tons / year; more than 90 kinds of Western medicine preparations, 2 billion tablets / year of solid preparations and 20 million injections / year. According to the development strategy of the enterprise, we have made great efforts to save energy, reduce consumption and protect the environment, passed the international environmental certification (ISO14000), vigorously developed the export business of API, and carried out the EU edmf and FDA certification, striving to gain a place in the international market. The company attaches great importance to technological innovation and new product development, and strengthens the combination of industry, University and research. The technology center of the group is the national recognized enterprise technology center and provincial engineering technology research center, with provincial enterprise academician workstation, national postdoctoral workstation and National Postdoctoral innovation center, undertaking a number of national key scientific research projects. Most of the company's products have independent intellectual property rights, core competitiveness and strong comprehensive competitiveness. Enterprise pursuit: committed to become the main service provider in the field of neuro mental health. Enterprise spirit: care, service, integrity, dedication, learning and innovation. Social responsibility: enha takes improving people's neuro mental health as its own responsibility, To make the greatest contribution to the improvement of the quality of life of the majority of patients with central nervous system diseases and their families. Basic objective: to provide patients with definite curative effect, high quality, low price, and a wide range of personalized drug system